Clinical trials
Graft Versus Host Disease clinical trials
Below are recruiting graft versus host disease clinical trials, each written for real people, not researchers. We’re tracking 122 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05675930RecruitingPhase 2
Light therapy for mouth GVHD after a stem cell transplant
This Phase 2 study tests a special light treatment (photobiomodulation) to improve oral graft-versus-host disease (GVHD) after a stem cell transplant. It may help people whose mouth symptoms have not improved with at least one prior treatment.
Bethesda, MarylandAges 4 years+ - NCT05531786RecruitingPhase 1/Phase 2
Pacritinib for hard-to-treat chronic graft-versus-host disease
This early-phase study tests pacritinib, a targeted medicine, for chronic graft-versus-host disease (cGVHD) that hasn’t improved after prior treatments. If you qualify, the goal is to reduce cGVHD symptoms and improve how well you function after a stem cell transplant.
Miami, FloridaAges 18–120 - NCT05470491RecruitingPhase 1/Phase 2
Haploidentical bone marrow transplant with GVHD prevention drugs
This trial tests a reduced-intensity bone marrow transplant from a related donor (haploidentical), using medicines to help prevent a serious complication called GVHD. It is for people with certain blood cancers and aims to improve outcomes by balancing transplant benefit with lower treatment intensity.
Bethesda, MarylandAges 12–120 - NCT05436418RecruitingPhase 1/Phase 2
Lower-dose transplant medicines to prevent graft-versus-host disease
This early-phase study tests a lower dose of cyclophosphamide given after a stem cell transplant to prevent graft-versus-host disease (GVHD). It also uses sirolimus and mycophenolate to improve how well the donor immune system accepts the transplant, aiming to reduce side effects while keeping protection against GVHD.
Duarte, CaliforniaAges 12–120 - NCT05443425RecruitingPhase 1
Leflunomide plus steroids for acute graft-versus-host disease
This early-phase trial tests whether adding leflunomide to standard steroid treatment can better control acute graft-versus-host disease (aGvHD) after a stem cell transplant. It may help reduce the immune reaction that damages the body while keeping treatment safe and manageable.
Duarte, CaliforniaAges 18 years+ - NCT05289167RecruitingPhase 1/Phase 2
Medicines to prevent graft-versus-host disease after a transplant
This trial tests a combination of medicines (post-transplant cyclophosphamide, bortezomib, and abatacept) to lower your chance of developing graft-versus-host disease (when transplanted immune cells attack your body) after a transplant. If you qualify, you’ll receive the study medicines as part of your post-transplant care and be followed closely to check safety and prevention of GvHD.
New Hyde Park, New YorkAges 14–100 - NCT05236062Recruiting
Exercise during steroid treatment for GVHD
This study looks at whether doing moderate-to-vigorous exercise can reduce complications from corticosteroids in people with newly diagnosed GVHD. It may help your body tolerate steroids better, while checking exercise safety during treatment.
Boston, MassachusettsAges 18 years+ - NCT05067595RecruitingPhase 1
Fecal transplant and fiber for gut graft-versus-host disease
This study tests whether a fecal microbiota transplant (a procedure that puts healthy donor bacteria into your gut) combined with a dietary fiber supplement can help treat gut graft-versus-host disease, a common complication after a stem cell transplant. It may help reduce diarrhea and other gut symptoms.
Seattle, WashingtonAges 18 years+ - NCT04660487Recruiting
How diet carbs affect GVHD after bone marrow transplant
This study looks at whether certain types of gut carbohydrates (called FODMAPs) are linked to graft-versus-host disease (GVHD) after a bone marrow transplant. It may help doctors understand how diet could influence symptoms and outcomes for people with specific blood cancers.
Suzhou, JiangsuAges 18–60 - NCT04886726RecruitingPhase 1
New medicine to prevent graft-versus-host disease after transplant
This Phase 1 study tests a new combination of medicines to prevent graft-versus-host disease (GVHD) after an allogeneic stem cell transplant. If it works well, it may lower the chance and severity of GVHD, which can affect skin, liver, and the gut.
Detroit, MichiganAges 18–70 - NCT04745221Recruiting
Fecal microbes therapy to help prevent graft-versus-host disease
This trial studies a treatment made from donor gut microbes to help prevent a common complication after a transplant called acute graft-versus-host disease (aGVHD). It may help by improving the balance and variety of gut bacteria during recovery after haploidentical transplant.
Suzhou, JiangsuAges 18–60 - NCT04744116RecruitingEarly Phase 1
Cord blood cell therapy added to ruxolitinib for steroid-resistant GVHD
This trial studies whether adding cord-blood–derived cells to ruxolitinib can improve steroid-resistant acute graft-versus-host disease (GVHD) affecting the lower gut or liver. It’s meant for people who are not getting better (or are worsening) despite adequate steroid treatment.
Houston, TexasAges 12–80 - NCT04710576RecruitingPhase 2
Axatilimab for chronic graft-versus-host disease
This trial tests a new drug called axatilimab to help patients whose chronic graft-versus-host disease (a condition where transplanted immune cells attack the body) isn't responding well to standard treatments. Researchers want to find the right dose and see if it can improve symptoms and quality of life.
Birmingham, AlabamaAges 2 years+ - NCT04380740RecruitingPhase 2
Longer vs shorter abatacept doses to prevent graft-versus-host disease
This trial tests whether giving abatacept for a longer or shorter time can better prevent graft-versus-host disease (a common complication after a stem cell transplant). If you’re having a planned unrelated donor transplant, the results may help reduce the risk or severity of transplant-related immune problems.
Duarte, CaliforniaAges 2 years+ - NCT04337515Recruiting
Study of a new method to prepare stem cell transplants
This feasibility study tests a technique called CLINIMACS to reduce certain immune cells (alpha/beta T-cells) before a stem cell transplant. It may help make the transplant safer and better controlled, but this is an early-stage feasibility test.
San Francisco, CaliforniaAges Up to 30 years - NCT03970096RecruitingPhase 2
Reduce graft-versus-host disease after stem cell transplant
This Phase 2 study tests ways to lower the risk of graft-versus-host disease (GVHD), a serious complication after an allogeneic stem cell transplant from a matched donor. It is for people with acute leukemia or MDS who are going to receive intensive conditioning therapy, aiming to improve safety while keeping the transplant effective.
Tampa, FloridaAges 1–60 - NCT03148743Recruiting
Fecal transplant for gut graft-versus-host disease
This study tests whether a fecal transplant (FMT) can help treat gut graft-versus-host disease (gut GVHD), a condition where donated immune cells attack the intestines. If you have gut GVHD and meet age requirements, you may be eligible to receive this treatment in the trial.
Suzhou, JiangsuAges 10–60 - NCT00128973Recruiting
Study immune system problems in people with unusual infections
This study looks at how the immune system works in people who have abnormal immune function, often shown by unusual or repeated infections or long-lasting inflammation. It may involve tests using blood samples and storage of blood for future research.
Bethesda, MarylandAges Any age - NCT00106925Recruiting
Long-term follow-up for people after stem cell transplant
This study follows people who are at least 3 years out from their first stem cell transplant to learn how they are doing long term. It may help improve future transplant care by tracking outcomes over time.
Bethesda, MarylandAges 7–80 - NCT00001529Recruiting
Bone marrow cell selection method study for transplants
This study tests improved ways to select and collect bone marrow cells from healthy donors for use in transplants. Researchers are looking for healthy volunteers to donate cells that may help people who need bone marrow transplants.
Bethesda, MarylandAges 18–60 - NCT00092235Recruiting
Understanding chronic graft-versus-host disease outcomes
This study follows patients who have had a stem cell transplant and developed chronic graft-versus-host disease (a condition where transplanted cells attack the body). Researchers will track your symptoms and collect blood samples to understand what affects how well patients do over time.
Bethesda, MarylandAges 1–120 - NCT07725263Recruiting
Low-dose antifungal for kids with low white blood cells
This trial tests a low dose of an antifungal medicine (liposomal amphotericin B) to prevent serious fungal infections in children whose immune system is weak after cancer treatment or a stem cell transplant. It's for kids aged 3 to 17 who are at high risk for these infections.
Haikou, HainanAges 3–17 - NCT07184853Recruiting
Ruxolitinib with etanercept vs ruxolitinib for severe GVHD
This trial tests whether adding etanercept to ruxolitinib works better than ruxolitinib alone for severe graft-versus-host disease (GVHD) that has not responded to steroids. GVHD is a common complication after a stem cell transplant where donor cells attack the patient's body.
Hangzhou, ZhejiangAges 12–70 - NCT07153276RecruitingPhase 4
Laser vs estrogen cream for vaginal dryness in Sjögren's
This trial compares two treatments for vaginal dryness in women with Sjögren's disease: a CO2 laser procedure versus a topical estrogen cream called promestriene. The goal is to see which option works better to relieve dryness and discomfort.
São Paulo, São PauloAges 30–65
Hear when a new Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for graft versus host disease?
- Yes. Clin2 currently lists 122 recruiting graft versus host disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a graft versus host disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a graft versus host disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.